Leerink Partners Upgrades AN2 Therapeutics to Outperform, Announces $9 Price Target
Benzinga Newsdesk 5 months ago
NewsUpgradesPrice TargetAnalyst Ratings
Leerink Partners analyst Joseph Schwartz upgrades AN2 Therapeutics (NASDAQ:ANTX) from Market Perform to Outperform and announces $9 price target.
Leerink Partners analyst Joseph Schwartz upgrades AN2 Therapeutics (NASDAQ:ANTX) from Market Perform to Outperform and announces $9 price target.